Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical leader pioneering targeted radiotherapies for advanced cancers, with a focus on acute myeloid leukemia (AML) and stem cell transplant conditioning. This page provides investors and healthcare professionals with timely updates on the company’s clinical trials, regulatory milestones, and scientific advancements.
Access verified news about Actinium’s antibody radiation conjugate (ARC) pipeline, including Iomab-B and Actimab-A, alongside strategic partnerships in oncology. Our curated repository ensures efficient tracking of developments in targeted radiotherapy, clinical research collaborations, and progress toward addressing unmet needs in hematologic malignancies.
Explore updates across key categories: clinical trial results, FDA communications, intellectual property expansions, and scientific presentations. Bookmark this page to stay informed on Actinium’s innovative approaches to minimizing treatment toxicity while improving outcomes for high-risk cancer patients.
Actinium Pharmaceuticals announced that multiple abstracts highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A, along with novel linker technology for solid tumors, have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting. The abstracts feature improved survival with both Iomab-B and Actimab-A in high-risk acute myeloid leukemia patients, including TP53 mutations. Actinium's presence at the SNMMI showcases its leadership in developing ARCs, with a focus on targeted radiotherapy for blood cancers and solid tumors.
Actinium Pharmaceuticals, Inc. announced a KOL webinar to discuss its Iomab-ACT trial with a leading FDA approved CAR T-cell therapy at the University of Texas Southwestern. The webinar will highlight the potential billion-dollar market opportunity in lymphodepletion. Dr. Farrukh Awan will lead the trial, aiming to study Iomab-ACT with an FDA approved CAR-T cell therapy for the first time. The company presented positive phase 1 trial results at the Tandem Meetings, showing promising safety and efficacy profiles. With the expanding CAR-T market and the need for improved conditioning in cellular therapy, Iomab-ACT presents a revenue opportunity in line with the growing patient population for cell and gene therapies.
FAQ
What is the current stock price of Actinium Pharmac (ATNM)?
What is the market cap of Actinium Pharmac (ATNM)?
